Discounted Cash Flow
Anika Therapeutics, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $103.4m | $32.5m | $9.8m | 31.5% | $2.22 |
| 2017 | $113.4m (9.7%) | $31.8m (-2.2%) | $31.8m (225.2%) | 28.1% (-10.9%) | $2.18 (-1.8%) |
| 2018 | $105.6m (-6.9%) | $18.7m (-41.2%) | $30.3m (-4.9%) | 17.7% (-36.8%) | $1.30 (-40.4%) |
| 2019 | $114.6m (8.6%) | $27.2m (45.2%) | $34.2m (12.9%) | 23.7% (33.8%) | $1.93 (48.5%) |
| 2020 | $130.5m (13.8%) | $-24.0m (-188.2%) | $11.4m (-66.5%) | -18.4% (-177.5%) | $-1.69 (-187.6%) |
| 2021 | $147.8m (13.3%) | $4.1m (117.2%) | $3.3m (-71.5%) | 2.8% (115.2%) | $0.29 (117.2%) |
| 2022 | $156.2m (5.7%) | $-14.9m (-459.4%) | $-3.1m (-194.6%) | -9.5% (-440.0%) | $-1.02 (-451.7%) |
| 2023 | $166.7m (6.7%) | $-82.7m (-456.3%) | $-7.2m (-134.5%) | -49.6% (-421.5%) | $-5.64 (-452.9%) |
| 2024 | $119.9m (-28.1%) | $-56.4m (31.8%) | $-2.3m (67.7%) | -47.0% (5.2%) | $-3.83 (32.1%) |
| 2025 | $112.8m (-5.9%) | $-10.9m (80.7%) | $4.4m (287.1%) | -9.6% (79.5%) | $-0.76 (80.2%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.